Sandip M. Honmane

Mr. Sandip M. Honmane

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2019 in Journal of Liposome Research
Verified
Journal Article
Closed access
SHSandip M. Honmane
Sandip M. Honmane
AHAshok Hajare
Ashok Hajare
HMHarinath More
Harinath More
RORiyaz Ali M. Osmani
Riyaz Ali M. Osmani
SSSachin Salunkhe
Sachin Salunkhe
The motive behind present work was to discover a solution for overcoming the problems allied with a deprived oral bioavailability of salbutamol sulfate (SS) due to its first pass hepatic metabolism, shorter half-life, and systemic toxicity at high doses. Pulmonary delivery provides an alternative route of administration to avoid hepatic metabolism of SS, moreover facilitated diffusion and prolonged retention can be achieved by incorporation into liposomes. Liposomes were prepared by thin film hydration technique using 32 full factorial design and formulation was optimized based on the vesicle size and percent drug entrapment (PDE) of liposomes. Optimized liposomal formulation exhibited an average size of about 167.2 ± 0.170 nm, with 80.68 ± 0.74% drug entrapment, and 9.74 ± 1.10 mV zeta potential. The liposomal dispersion was then spray dried and further characterized for in-vitro aerosol performance using Andersen Cascade Impactor. Optimized liposomal formulation revealed prolonged in-vitro drug release of more than 90% up to 14 h following Higuchi’s controlled release model. Thus, the proposed new-fangled liposomal formulation would be a propitious alternative to conventional therapy for efficient and methodical treatment of asthma and alike respiratory ailments.

13 July 2022 in OpenNano
Verified
Journal Article
Open access
SHSandip M. Honmane
Sandip M. Honmane
MCManoj S. Charde
Manoj S. Charde
SSSachin S. Salunkhe
Sachin S. Salunkhe
PCPrafulla B. Choudhari
Prafulla B. Choudhari
SNSopan N. Nangare
Sopan N. Nangare

17 January 2023 in Polymers
Verified
Journal Article
Open access
PDF file
YAYahya Alhamhoom
Yahya Alhamhoom
SHSandip M. Honmane
Sandip M. Honmane
UHUmme Hani
Umme Hani
RORiyaz Ali M Osmani
Riyaz Ali M Osmani
GKGeetha Kandasamy
Geetha Kandasamy
MCManoj S. Charde
Manoj S. Charde
Piroxicam is a Biopharmaceutical Classification System (BCS) Class II drug having poor aqueous solubility and a short half-life. The rationale behind the present research was to develop a Piroxicam nanosuspension to enhance the solubility and thereby the in vitro bioavailability of the drug. Piroxicam nanosuspension (PRX NS) was prepared by an anti-solvent precipitation technique and optimized using a full-factorial design. Herein, the nanosuspension was prepared using polymer polyvinylpyrrolidone (PVP) K30® and Poloxamer 188® as a stabilizer to improve the solubility and in vitro bioavailability of the drug. Nine formulations were prepared based on 32 full-factorial experimental designs to study the effect of the formulation variables such as concentration of poloxamer 188 (%) (X1) and stirring speed (rpm) (X2) as a process variable on the response of particle size (nm) and solubility (µg/mL). The prepared NS was characterized by phase solubility, Fourier-transform infrared (FT-IR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), transmission electron microscopy (TEM), particle size, zeta potential, entrapment efficiency, and percent drug release. DSC and XRPD analysis of freeze-dried NS formulation showed conversion of PRX into a less crystalline form. NS formulations showed a reduction in the size from 443 nm to 228 nm with −22.5 to −30.5 mV zeta potential and % drug entrapment of 89.76 ± 0.76. TEM analysis confirmed the size reduction at the nano level. The solubility was increased from 44 μg/mL to 87 μg/mL by altering the independent variables. The solubility of PRX NS in water was augmented by 14- to 15-fold (87.28 μg/mL) than pure PRX (6.6 μg/mL). The optimized formulation (NS9) at drug-to-stabilizer concentration exhibited a greater drug release of approximately 96.07% after 120 min as compared to the other NS formulations and pure PRX (36.78%). Thus, all these results revealed that the prepared NS formulations have improved the solubility and in vitro dissolution compared to the pure drug. Furthermore, an increase in the drug release was observed from the NS than that of the pure PRX. All these outcomes signified that the prepared PRX NS showed an increase in solubility and in vitro dissolution behavior; which subsequently would aid in attainment of enhanced bioavailability.
1

3 March 2020 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
SHSandip M. Honmane
Sandip M. Honmane
SCSagar Maruti Chimane
Sagar Maruti Chimane
SBSandip Akaram Bandgar
Sandip Akaram Bandgar
SPShitalkumar Shivagonda Patil
Shitalkumar Shivagonda Patil

20 June 2023 in Acta Chimica Slovenica
Verified
Journal Article
Open access
PDF file
SHSandip M. Honmane
Sandip M. Honmane
MCManoj S. Charde
Manoj S. Charde
RORiyaz Ali M. Osmani
Riyaz Ali M. Osmani
The objective of the current study was to develop and optimize a novel lyophilized liposomal formulation of anticancer agent carmustine, or bis-chloroethyl nitrosourea (BCNU) for prolonged release that could overcome the dose-dependent side effects and improve its bioavailability at the site of action. The optimization was done using a 32 factorial design approach wherein soya phosphatidylcholine (SPC) and cholesterol (CH) as independent variables. The optimized formulation (F4) exhibited high entrapment efficiency (81.57%) with an average vesicle size of 141.7 nm and a −22.6 mV Zeta potential. In-vitro drug release studies from all formulations revealed that the BCNU was released for up to 36 hours following the Higuchi matrix release model. The TEM, FTIR, DSC, PXRD, and SEM analyses confirm the formation of liposomes. BCNU-loaded nanoliposomal formulation demonstrated prolonged release, suggesting that it could be used to supplement cancer therapy efficiently with a reduction in dose-dependent side effects.

8 November 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SHSandip M. Honmane
Sandip M. Honmane
MCManoj S. Charde
Manoj S. Charde
PCPrafulla B. Choudhari
Prafulla B. Choudhari
NJNamdeo R. Jadhav
Namdeo R. Jadhav